- Home
- GILD vs DHR Comparison
GILD vs DHR Comparison
Compare GILD & DHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- DHR
- Stock Information
- Founded
- GILD 1987
- DHR 1969
- Country
- GILD United States
- DHR United States
- Employees
- GILD N/A
- DHR N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- DHR Industrial Machinery/Components
- Sector
- GILD Health Care
- DHR Industrials
- Exchange
- GILD Nasdaq
- DHR Nasdaq
- Market Cap
- GILD 133.3B
- DHR 135.4B
- IPO Year
- GILD 1992
- DHR N/A
- Fundamental
- Price
- GILD $111.63
- DHR $200.41
- Analyst Decision
- GILD Buy
- DHR Strong Buy
- Analyst Count
- GILD 25
- DHR 18
- Target Price
- GILD $110.17
- DHR $265.47
- AVG Volume (30 Days)
- GILD 8.9M
- DHR 3.9M
- Earning Date
- GILD 08-07-2025
- DHR 07-22-2025
- Dividend Yield
- GILD 2.83%
- DHR 0.64%
- EPS Growth
- GILD 1118.07
- DHR N/A
- EPS
- GILD 4.73
- DHR 5.16
- Revenue
- GILD $28,735,000,000.00
- DHR $23,820,000,000.00
- Revenue This Year
- GILD $1.59
- DHR $3.56
- Revenue Next Year
- GILD $3.67
- DHR $6.44
- P/E Ratio
- GILD $23.62
- DHR $39.00
- Revenue Growth
- GILD 4.68
- DHR 0.35
- 52 Week Low
- GILD $66.01
- DHR $171.00
- 52 Week High
- GILD $119.96
- DHR $281.70
- Technical
- Relative Strength Index (RSI)
- GILD 58.05
- DHR 54.92
- Support Level
- GILD $104.46
- DHR $196.02
- Resistance Level
- GILD $112.00
- DHR $205.04
- Average True Range (ATR)
- GILD 2.78
- DHR 4.42
- MACD
- GILD 0.05
- DHR 0.08
- Stochastic Oscillator
- GILD 89.70
- DHR 58.42
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About DHR Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.